Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator
J Primo,
P Geelen,
J Brugada,
AL Filho,
L Mont,
F Wellens,
M Valentino,
and
P Brugada
Cardiovascular Center, Onze Lieve Vrouw Hospital, Aalst, Belgium.
OBJECTIVES: We report the occurrence of cardiac events during long-term follow-up in patients with hypertrophic cardiomyopathy (HCM) after cardioverter-defibrillator implantation. BACKGROUND: The identification of patients at high risk for sudden death and the prevention of recurrence of sudden death in HCM represents a difficult problem. METHODS: We retrospectively analyzed the occurrence of cardiac events during follow-up of 13 patients with HCM who received an implantable cardioverter-defibrillator (ICD) because of aborted sudden death (n = 10) or sustained ventricular tachycardia (n = 3) (group I). Findings were compared with those in 215 patients with an ICD and other structural heart disease or idiopathic ventricular fibrillation (group II). RESULTS: After a mean (+/-SD) follow-up period of 26+/-18 months, 2 of 13 patients in group I received appropriate shocks. The calculated cumulative incidence of shocks was 21% in group I and 66% in group II after 40 months (p < 0.05). We observed a low incidence of recurrence of ventricular tachycardia/fibrillation during follow-up in patients with HCM. No deaths occurred. CONCLUSIONS: Our data suggest that ventricular tachyarrhythmias may not always be the primary mechanism of syncope and sudden death in patients with HCM. The ICD seems to have a less important impact on prognosis in patients with HCM than in patients with other etiologies of aborted sudden death.
This article has been cited by other articles:
|
|
|
|
 
C. O'Mahony, P. D. Lambiase, G. Quarta, M. Cardona, M. Calcagnino, K. Tsovolas, S. Al-Shaikh, S. M. Rahman, S. Arnous, S. Jones, et al.
The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy
Heart,
January 15, 2012;
98(2):
116 - 125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, P. Spirito, W.-K. Shen, T. S. Haas, F. Formisano, M. S. Link, A. E. Epstein, A. K. Almquist, J. P. Daubert, T. Lawrenz, et al.
Implantable Cardioverter-Defibrillators and Prevention of Sudden Cardiac Death in Hypertrophic Cardiomyopathy
JAMA,
July 25, 2007;
298(4):
405 - 412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pedrote, F. J. Morales, L. Garcia-Riesco, and F. Errazquin
Documented exercise-induced cardiac arrest in a paediatric patient with hypertrophic cardiomyopathy
Europace,
June 1, 2006;
8(6):
430 - 433.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. J. Maron, N. A. M. Estes III, M. S. Maron, A. K. Almquist, M. S. Link, and J. E. Udelson
Primary Prevention of Sudden Death as a Novel Treatment Strategy in Hypertrophic Cardiomyopathy
Circulation,
June 17, 2003;
107(23):
2872 - 2875.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Elliott, J. Poloniecki, S. Dickie, S. Sharma, L. Monserrat, A. Varnava, N. G. Mahon, and W. J. McKenna
Sudden death in hypertrophic cardiomyopathy: identification of high risk patients
J. Am. Coll. Cardiol.,
December 1, 2000;
36(7):
2212 - 2218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.C. Saumarez and A.A. Grace
Paced ventricular electrogram fractionation and sudden death in hypertrophic cardiomyopathy and other non-coronary heart diseases
Cardiovasc Res,
July 1, 2000;
47(1):
11 - 22.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Elliott, S. Sharma, A. Varnava, J. Poloniecki, E. Rowland, and W. J. McKenna
Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy
J. Am. Coll. Cardiol.,
May 1, 1999;
33(6):
1596 - 1601.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
